Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study

Since the discovery of the critical role played by angiogenesis in tumor growth and development (1), there has been increased interest in evaluating anti-angiogenic agents in the treatment of various malignancies, including non-small-cell lung cancer (NSCLC). Bevacizumab is a humanized monoclonal antibody to vascular endothelial growth factor (VEGF) and is approved for use in combination with chemotherapy in multiple countries for the treatment of patients with metastatic NSCLC.